ContextVision announces the signing of a strategic clinical development
partnership with the University of Washington School of Medicine in Seattle. The
collaboration will focus on acquiring a medical imaging dataset to identify a
multiparameter biomarker for screening and staging metabolic dysfunction
-associated steatotic liver disease (MASLD). This marks an important step toward
developing ContextVision's new product line within data quality ultrasound.

ContextVision, a global market leader in medical imaging solutions, has
partnered with the University of Washington, a top ten university that is
globally recognized for its research and clinical excellence. The university's
healthcare system, UW Medicine, brings significant clinical expertise and
research capabilities to this collaboration.

At the end of 2023, ContextVision launched a strategic venture into data
quality, expanding beyond its established business focus on image quality. The
new business initiative aims to pioneer AI-based solutions capable of
interpreting organ-specific imaging data to enable physiological quantification
biomarkers. The partnership with the UW School of Medicine's Department of
Radiology and Division of Gastroenterology represents a major milestone in this
strategic initiative, with the potential to aid the early detection and
monitoring of MASLD.

"We are thrilled to announce this strategic partnership with a top-tier medical
school in clinical and radiological research. This is a critical step toward our
vision of developing multiple products within data quality and liver disease
management," says Gerald Pötzsch, CEO of ContextVision. "The potential in this
field is tremendous, and over time, if everything aligns, I believe data quality
will become our largest business area."

Data collection and clinical collaboration to revolutionize MASLD diagnosis

The partnership seeks to provide more accurate, and earlier, detection of MASLD
using ultrasound, potentially transforming patient outcomes compared to current
diagnostic methods.

"Healthcare technology is rapidly evolving, and we have a responsibility to
improve the capabilities and efficiencies of healthcare through clinical
translation and adoption of advanced technologies. The goal of this
collaboration is to accelerate the rate of translation of our research to
patient care and offer improved patient outcomes," said Dr. Dushyant Sahani, UW
chair and professor of radiology.

The UW Medicine healthcare system cares for a large volume of patients with
MASLD.

This patient volume allows for a comprehensive overview of disease progression,
from early to advanced stages, enhancing the quality of radiological datasets.

UW Medicine project co-leads are Dr. Manish Dhyani, radiology's director of
research and clinical translation in ultrasound, and Dr. Rotonya Carr, division
head of gastroenterology. They expressed hope that this collaboration of
radiologists, hepatologists and ContextVision's software engineers will improve
the diagnostic journey as well as patient experience and outcomes.

The UW School of Medicine also provides a state-of-the-art digital imaging
research center, ensuring the highest standards of clinical research. The
collaboration will focus on gathering extensive clinical, ultrasound, and
magnetic resonance imaging datasets, tracking disease progression with a rich
digital repository of advanced physiological insights for new product
development. As the project progresses, ContextVision will announce key
milestones and additional strategic partnerships to support this venture.
ContextVision will also announce further details about the study once it is
approved and the first patient is enrolled.

Large market potential and future growth in digital biomarkers

ContextVision recognizes the substantial market potential in developing digital
biomarkers for MASLD. The vision is to develop multiple products over the coming
five years, empowering our customer's advanced diagnostic solutions.
ContextVision also plans to expand into digital biomarkers targeting other organ
systems, building a comprehensive suite of data quality solutions for additional
diseases. This expansion into data quality is anticipated to contribute
substantially to ContextVision's long-term growth trajectory.

The urgent need for advanced liver disease solutions

Today, one in four Americans is at risk of fatty liver, a life-threatening
condition, affecting nearly 100 million people in the U.S. alone. In China, the
prevalence is more than double, with over 200 million affected individuals. On a
global scale, the number of people suffering from liver diseases is expected to
rise significantly the coming years. With the cost of treating liver diseases
exceeding hundreds of billions of USD globally each year, there is an urgent
need for advanced technologies to monitor liver health and for solutions that
can reduce the overall cost of care.*

*American Liver Foundation, American Association for the Study of Liver
Diseases, Journal of Hepatology

For more information, please contact

Gerald Pötzsch

Chief Executive Officer, ContextVision
gerald.potzsch@contextvision.com

About ContextVision
ContextVision is a medical technology software company specialized in
imageanalysis and artificial intelligence. As the global market leader within
imageenhancement, we are a trusted partner to leading manufacturers of
ultrasound, X-ray and MRI equipment around the world. Our expertise is to
develop powerfulsoftware products, based on proprietary technology and
artificial intelligencefor image-based applications. Our cutting-edge technology
helps cliniciansaccurately interpret medical images, a crucial foundation for
better diagnosisand treatment. The company, established in 1983, is based in
Sweden with localrepresentation in the U.S., Japan, China and Korea.
ContextVision is listed onthe Oslo Stock Exchange under the ticker CONTX.